Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.06
BIOS's Cash to Debt is ranked lower than
81% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 0.34 vs. BIOS: 0.06 )
Ranked among companies with meaningful Cash to Debt only.
BIOS' s 10-Year Cash to Debt Range
Min: 0  Med: 0.80 Max: No Debt
Current: 0.06
Equity to Asset 0.24
BIOS's Equity to Asset is ranked lower than
77% of the 202 Companies
in the Global Medical Care industry.

( Industry Median: 0.45 vs. BIOS: 0.24 )
Ranked among companies with meaningful Equity to Asset only.
BIOS' s 10-Year Equity to Asset Range
Min: 0.24  Med: 0.44 Max: 0.75
Current: 0.24
0.24
0.75
F-Score: 2
Z-Score: 0.52
M-Score: -3.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -8.41
BIOS's Operating margin (%) is ranked lower than
86% of the 210 Companies
in the Global Medical Care industry.

( Industry Median: 7.02 vs. BIOS: -8.41 )
Ranked among companies with meaningful Operating margin (%) only.
BIOS' s 10-Year Operating margin (%) Range
Min: -11.69  Med: 0.74 Max: 4.61
Current: -8.41
-11.69
4.61
Net-margin (%) -14.09
BIOS's Net-margin (%) is ranked lower than
88% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 3.29 vs. BIOS: -14.09 )
Ranked among companies with meaningful Net-margin (%) only.
BIOS' s 10-Year Net-margin (%) Range
Min: -16.05  Med: -0.54 Max: 9.77
Current: -14.09
-16.05
9.77
ROE (%) -53.24
BIOS's ROE (%) is ranked lower than
94% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 8.74 vs. BIOS: -53.24 )
Ranked among companies with meaningful ROE (%) only.
BIOS' s 10-Year ROE (%) Range
Min: -57.57  Med: -1.43 Max: 43.05
Current: -53.24
-57.57
43.05
ROA (%) -16.44
BIOS's ROA (%) is ranked lower than
91% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. BIOS: -16.44 )
Ranked among companies with meaningful ROA (%) only.
BIOS' s 10-Year ROA (%) Range
Min: -27.23  Med: -0.22 Max: 20.26
Current: -16.44
-27.23
20.26
ROC (Joel Greenblatt) (%) -78.83
BIOS's ROC (Joel Greenblatt) (%) is ranked lower than
92% of the 211 Companies
in the Global Medical Care industry.

( Industry Median: 15.85 vs. BIOS: -78.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -902.86  Med: 6.11 Max: 227.09
Current: -78.83
-902.86
227.09
Revenue Growth (3Y)(%) 12.20
BIOS's Revenue Growth (3Y)(%) is ranked higher than
73% of the 155 Companies
in the Global Medical Care industry.

( Industry Median: 8.20 vs. BIOS: 12.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BIOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -35  Med: 4.50 Max: 15.9
Current: 12.2
-35
15.9
EPS Growth (3Y)(%) 493.40
BIOS's EPS Growth (3Y)(%) is ranked higher than
99% of the 113 Companies
in the Global Medical Care industry.

( Industry Median: 9.90 vs. BIOS: 493.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BIOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -82.7  Med: -21.50 Max: 493.4
Current: 493.4
-82.7
493.4
» BIOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BIOS Guru Trades in Q2 2014

Mario Gabelli 1,440,840 sh (+75.98%)
Mario Gabelli 2,255,552 sh (+175.48%)
Pioneer Investments 280,320 sh (unchged)
Steven Cohen 416,500 sh (unchged)
Ron Baron 144,010 sh (unchged)
» More
Q3 2014

BIOS Guru Trades in Q3 2014

Ron Baron 281,300 sh (+95.33%)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 2,593,352 sh (unchged)
Mario Gabelli 2,593,352 sh (unchged)
Mario Gabelli 1,431,426 sh (-0.65%)
Steven Cohen 92,100 sh (-77.89%)
» More
Q4 2014

BIOS Guru Trades in Q4 2014

Ron Baron 345,500 sh (+22.82%)
Pioneer Investments 280,320 sh (unchged)
Mario Gabelli 4,171,782 sh (unchged)
Mario Gabelli 4,171,782 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 1,178,601 sh (-17.66%)
» More
Q1 2015

BIOS Guru Trades in Q1 2015

Mario Gabelli 1,300,981 sh (+10.38%)
Ron Baron 372,500 sh (+7.81%)
Mario Gabelli 7,666,300 sh (+14.97%)
Louis Moore Bacon 130,000 sh (unchged)
Pioneer Investments 280,320 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on BioScrip Inc

Baron Funds Comments on BioScrip Inc. - Feb 26, 2014

BioScrip, Inc. (NASDAQ:BIOS), an operator of infusion therapy pharmacies, fell 16.5% for the Fund in the quarter. While the company continues to execute its strategy of consolidating the infusion services industry, it stumbled after a non-core legacy business performed worse than expected. While the miscue is not dire for the company, it hurt management's credibility after it had to reset guidance. We continue to believe there is substantial value and growth in the core infusion business, and that this has been validated by CVS's purchase in December of the number two player in the space, Coram, for a very high multiple of cash flow.



From Ron Baron (Trades, Portfolio)'s Baron Funds fourth quarter 2013 letter to shareholders.

Check out Ron Baron latest stock trades

Top Ranked Articles about BioScrip Inc

Two Gurus Hold Stakes in Embattled BioScrip
BioScrip Inc (NASDAQ:BIOS), a New York-based national provider of infusion and home care management solutions, announced last month the sale of $62.5 million in Series A Convertible Preferred Stock to Coliseum Capital Management, LLC, and related funds. Read more...
A Look at Mario Gabelli's Latest Stake Increases
Mario Gabelli (Trades, Portfolio) has continued to use the same formula for success since 1976 when he founded GAMCO Investors. The firm has continued to use a bottom-up research strategy with a consistent investment process. Read more...
Mario Gabelli Boosts BioScrip Inc. Position
Mario Gabelli (Trades, Portfolio), the founder of the $49.4 billion asset management firm GAMCO Investors (NYSE:GBL), has increased his stake in BioScrip Inc. (NASDAQ:BIOS), according to GuruFocus Real Time Picks. Gabelli holds 3,636,600 shares, or 5.3% of the company, after the 40.2% position increase. Read more...

Ratios

vs
industry
vs
history
Forward P/E 22.37
BIOS's Forward P/E is ranked lower than
68% of the 93 Companies
in the Global Medical Care industry.

( Industry Median: 19.31 vs. BIOS: 22.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 0.85
BIOS's P/B is ranked higher than
93% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 2.74 vs. BIOS: 0.85 )
Ranked among companies with meaningful P/B only.
BIOS' s 10-Year P/B Range
Min: 0.3  Med: 1.41 Max: 3.1
Current: 0.85
0.3
3.1
P/S 0.17
BIOS's P/S is ranked higher than
98% of the 218 Companies
in the Global Medical Care industry.

( Industry Median: 1.49 vs. BIOS: 0.17 )
Ranked among companies with meaningful P/S only.
BIOS' s 10-Year P/S Range
Min: 0.04  Med: 0.24 Max: 1.89
Current: 0.17
0.04
1.89
Current Ratio 1.46
BIOS's Current Ratio is ranked higher than
56% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. BIOS: 1.46 )
Ranked among companies with meaningful Current Ratio only.
BIOS' s 10-Year Current Ratio Range
Min: 0.86  Med: 1.34 Max: 2.76
Current: 1.46
0.86
2.76
Quick Ratio 1.17
BIOS's Quick Ratio is ranked lower than
51% of the 203 Companies
in the Global Medical Care industry.

( Industry Median: 1.19 vs. BIOS: 1.17 )
Ranked among companies with meaningful Quick Ratio only.
BIOS' s 10-Year Quick Ratio Range
Min: 0.79  Med: 1.17 Max: 2.5
Current: 1.17
0.79
2.5
Days Inventory 17.87
BIOS's Days Inventory is ranked lower than
51% of the 152 Companies
in the Global Medical Care industry.

( Industry Median: 17.78 vs. BIOS: 17.87 )
Ranked among companies with meaningful Days Inventory only.
BIOS' s 10-Year Days Inventory Range
Min: 0.52  Med: 10.48 Max: 80.5
Current: 17.87
0.52
80.5
Days Sales Outstanding 49.56
BIOS's Days Sales Outstanding is ranked lower than
55% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 46.60 vs. BIOS: 49.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOS' s 10-Year Days Sales Outstanding Range
Min: 23.97  Med: 47.80 Max: 164.17
Current: 49.56
23.97
164.17

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.69
BIOS's Price/Median PS Value is ranked higher than
89% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 1.18 vs. BIOS: 0.69 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOS' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 0.98 Max: 5.61
Current: 0.69
0.21
5.61
Earnings Yield (Greenblatt) (%) -16.12
BIOS's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 4.10 vs. BIOS: -16.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -16.18  Med: 3.10 Max: 9.5
Current: -16.12
-16.18
9.5
Forward Rate of Return (Yacktman) (%) -84.47
BIOS's Forward Rate of Return (Yacktman) (%) is ranked lower than
100% of the 101 Companies
in the Global Medical Care industry.

( Industry Median: 10.96 vs. BIOS: -84.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BIOS' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -88.6  Med: -1.60 Max: 45.1
Current: -84.47
-88.6
45.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:SHDMF, APNHF, GNC, JCOUF, PMC » details
Traded in other countries:MM6.Germany,
BioScrip Inc, formerly known as MIM Corporation, was incorporated in Delaware in 1996. The Company provides home infusion and other home healthcare services to patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivers cost-effective access to prescription medications and home health services. Its services are provided in coordination with, and under the direction of the patient's physicians. The Company operates in three reportable segments: Infusion Services, Home Health Services, and Pharmacy Benefit Management Services. Its Infusion Services segment provides services consisting of home infusion therapy, respiratory therapy and the provision of durable medical equipment products and services. Infusion Services include the dispensing and administering of infusion-based drugs, which requires additional nursing and clinical management services, equipment to administer the correct dosage and patient training designed to improve patient outcomes. Home Health Services provides services that include the provision of skilled nursing services and therapy visits, private duty nursing services, hospice services, rehabilitation services and medical social services to patients primarily in their home. The integrated Pharmacy Benefit Management Services' operating and reportable segment consists of discount card programs. The discount card programs provide a cost effective alternative for individuals who may be uninsured, underinsured or may have restrictive coverage that disallows reimbursement for certain medications. The discount card allows an individual to receive prescription medications at a discounted price compared to the retail price. The Company has approximately 250 sales and marketing representatives and over 1,000 payor relationships including MCOs, Medicare Part D pharmacy networks, other government programs such as Medicare and Medicaid and other Third Party Payors. The sales and marketing efforts are focused on payors, healthcare systems and physician prescribers and are driven by dedicated managed care and physician sales teams as well as home health care consultants. PBM Services has over 100 relationships with PBM clients, including Medicaid MCOs, employers, TPAs, workers compensation providers and discount card marketers. The Company undertakes direct sales methods to promote the discount card program and add new marketing organizations. The Company owns trademarks, trade names and service marks including BioScrip, BioScrip Infusion Services, BioScrip Medical Supply Services, BioScrip PBM Services, BioScrip Pharmacy Services, Applied Health Care, CarePoint Partners, Critical Homecare Solutions, Deaconess HomeCare, Deaconess Hospice, among others. The Company's competitors within the home infusion market include Walgreen Co., including OptionCare and Critical Care Systems; CVS Caremark Corp., through its recent acquisition of the Coram infusio
» More Articles for BIOS

Headlines

Articles On GuruFocus.com
5-year lows: Elizabeth Arden Inc, Systemax Inc, BioScrip Inc, and Thompson Creek Metals Co Inc. May 26 2015 
5-year lows: Resource Capital Corp, Dynex Capital Inc, BioScrip Inc, and Kemet Corp. May 10 2015 
Two Gurus Hold Stakes in Embattled BioScrip Apr 07 2015 
A Look at Mario Gabelli's Latest Stake Increases Apr 01 2015 
Mario Gabelli Ups Stake in BioScript, But Value of Stock Declines Mar 18 2015 
A Look at Mario Gabelli's New Added Positions Feb 04 2015 
Mario Gabelli Boosts BioScrip Inc. Position Oct 28 2014 
Soros and Gabelli Top Guru Real Time Picks of the Week Aug 08 2014 
Gurus' Real Time Stock Picks of the Week May 09 2014 
Morning Coffee: Real-Time Picks May 07 2014 

More From Other Websites
BioScrip, Inc. Announces Expiration and Results of Rights Offering Jul 28 2015
BIOSCRIP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Jul 28 2015
BioScrip, Inc. Announces Expiration and Results of Rights Offering Jul 28 2015
BioScrip Reports First Quarter 2015 Financial Results Jul 17 2015
BIOSCRIP, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 19 2015
BioScrip Announces Completion Of Exchange Offer For Its 8.875% Senior Notes Due 2021 Jun 19 2015
BioScrip Announces Completion Of Exchange Offer For Its 8.875% Senior Notes Due 2021 Jun 19 2015
BioScrip, Inc. Announces Record Date for Rights Offering Jun 18 2015
BioScrip, Inc. Announces Record Date for Rights Offering Jun 18 2015
BIOSCRIP, INC. Files SEC form 8-K, Other Events Jun 18 2015
BIOSCRIP, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 10 2015
BioScrip Announces Extension Of Expiration Date Of Exchange Offer For Its 8.875% Senior Notes Due... Jun 10 2015
BIOSCRIP, INC. Files SEC form 8-K, Regulation FD Disclosure May 29 2015
BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers May 27 2015
BioScrip's Loss, Margins Worry; Infusion Services Offers Hope - Analyst Blog May 19 2015
13F Watch: Krevlin's Glenhill Advisors Buys Pier 1, Nexstar; Slashes American Airlines, Jamba May 18 2015
BIOSCRIP, INC. Financials May 15 2015
BIOSCRIP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters... May 14 2015
BioScrip (BIOS) Q1 Loss Wider than Expected; Revenues Beat - Analyst Blog May 12 2015
10-Q for BioScrip, Inc. May 11 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK